A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of
GDC-0980 in patients with recurrent or persistent endometrial cancer. The safety,
tolerability, and pharmacokinetics of GDC-0980 will also be evaluated.